ACP
TEVA icon

Arrowgrass Capital Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Arrowgrass Capital Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-311,981
Closed -$16.7M – 33
2016
Q1 		$16.7M Sell
311,981
-88,019
-22% -$5.16M 4.91% 5
2015
Q4 		$26.3M Buy
+400,000
New +$24.7M 6.94% 4

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Arrowgrass Capital Partners's TEVA Position: Q2 2016 in Review

Arrowgrass Capital Partners sold out of Teva Pharmaceuticals (TEVA) in Q2 2016, closing a stake of 311,981 shares — an estimated $16.7M sold.

Arrowgrass Capital Partners first reported a position in TEVA in Q4 2015 and held it in 2 quarters. The position peaked at $26.3M in Q4 2015. 813 funds tracked by Wall St. Rank hold TEVA as of Q2 2016.

  • Arrowgrass Capital Partners reported no remaining Teva Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Arrowgrass Capital Partners sold 311,981 Teva Pharmaceuticals shares in Q2 2016, an estimated $16.7M.
  • Arrowgrass Capital Partners first reported a position in Teva Pharmaceuticals in Q4 2015 and held it in 2 quarters.
  • Arrowgrass Capital Partners's Teva Pharmaceuticals position peaked at $26.3M in Q4 2015.
  • 813 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2016.

Based on Arrowgrass Capital Partners's 13F filing for Q2 2016, filed 15 Aug 2016.